David McIntosh: How European Plasma Policy Shapes Global Access to Life-Saving Therapies
David McIntosh, Founder and Chair of United Plasma Action, shared Expresso’s post on LinkedIn:
“This excellent post highlights a stubborn problem that has afflicted the European Union throughout this Century – doing great damage, not only to European Healthcare but to Healthcare globally.
In the field of vital plasma-derived medicines (of which there’s a fatal global shortage)
European institutions lounge luxuriously in a self-important but utterly delusional feeling of superior morality, based on pseudo-ethical notions about the sanctity of ‘Substances of Human Origin‘.
Less self-indulgent philosophers recognize that the important thing about life-saving plasma-derived medicines is not their origin, but their destination.
They are produced for one purpose and for one purpose only – to provide patients with the treatments they need.
All over the World, rare disease sufferers are going through untold trauma and succumbing to an early death, simply due to a lack of plasma-derived medicines.
One would sincerely expect therefore that every Healthcare organization in the World would be doing its best to help increase the global plasma harvest – but what is Europe doing … ?
For instance …
- what is the EU doing?
- what is it’s SUPPLY team doing?
- what is the European Blood Alliance doing?
- what contribution is being made by the International Plasma and Fractionation Association?
The sad fact is that they are all misguidedly inhibiting progress towards improving the plasma harvest, both in Europe and globally – to the deep detriment of patients everywhere – detriment and death.
That’s what’s genuinely unethical.
It really does have to stop.”
Expresso shared a post on LinkedIn:
“Fragility.
Portugal spends 100 million euros a year on medicines made from plasma and imports 89 percent of the raw material, mainly from the USA.
Experts warn of the ethical, financial and geopolitical risks of this insufficiency.
Read more.”
Stay updated with Hemostasis Today.
-
May 23, 2026, 16:55Rahul Bhargava: Ensure Equal Recognition of Clinical Haematologists in Blood Cancer Clinical Trials
-
May 23, 2026, 16:44Brian O Mahony: World Haemophilia Day Receives Global WHO Recognition
-
May 23, 2026, 16:44Yusuf Hameed: Gene Therapy Could Reduce Lifetime Treatment Burden in Hemophilia A
-
May 23, 2026, 16:43Chokri Ben Lamine: Pacritinib Is a Key JAK Inhibitor for Cytopenic Myelofibrosis
-
May 23, 2026, 16:42Bartosz Hudzik: Bleeding Risk Alone Should Not Determine Treatment Intensity
-
May 23, 2026, 16:42Shimels Tessema: Celebrating the WHA Resolution on Hemophilia and Other Bleeding Disorders
-
May 23, 2026, 16:38José Octavio Alva Bucio: Securing the Future of Plasma and Blood-Derived Medicines
-
May 23, 2026, 16:33Why Are We Dismantling What Powers Humanity and the Global Economy? – ASH
-
May 23, 2026, 16:24Marc Wittwer: A Practical Viscoelastic-Guided Algorithm for Trauma-Induced Coagulopathy in Clinical Workflow